Recursion Pharmaceuticals (RXRX) CSO equity holdings detailed in Form 3

Rhea-AI Filing Summary

Recursion Pharmaceuticals’ CSO David Hallett filed a Form 3 disclosing his initial beneficial ownership in the company’s Class A common stock and equity awards as of 01/01/2026. He directly holds 287,928 shares of Class A common stock, plus restricted stock units (RSUs) covering 277,759 and 28,454 shares. These RSUs vest in equal quarterly installments from February 15, 2025 through November 15, 2028, and from May 15, 2025 through February 15, 2029, contingent on continued service.

Hallett also holds multiple stock options on Class A common shares, including options for 70,037 shares at $7.25 and 740,686 shares at $6.09, each vesting monthly after initial vesting dates in 2025. Additional options with a $0.01 exercise price cover tranches such as 56,531, 75,375, 80,510, 9,241, and 150,888 shares, with some already fully exercisable and others vesting quarterly through dates extending to March 15, 2028, including awards assumed in the acquisition of Exscientia plc.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hallett David

(Last) (First) (Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UT 84101

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2026

3. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CSO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Class A Common Stock	287,928	D
Class A Common Stock	277,759(1)	D
Class A Common Stock	28,454(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(3)	02/02/2035	Class A Common Stock	70,037	$7.25	D
Stock Option (Right to Buy)	(4)	12/18/2034	Class A Common Stock	740,686	$6.09	D
Stock Option (Right to Buy)	(5)	03/31/2032	Class A Common Stock	56,531	$0.01	D
Stock Option (Right to Buy)	(6)	03/31/2032	Class A Common Stock	75,375	$0.01	D
Stock Option (Right to Buy)	04/04/2026(7)	04/02/2033	Class A Common Stock	80,510	$0.01	D
Stock Option (Right to Buy)	(8)	04/02/2033	Class A Common Stock	80,510	$0.01	D
Stock Option (Right to Buy)	03/15/2025(9)	04/14/2034	Class A Common Stock	9,241	$0.01	D
Stock Option (Right to Buy)	04/17/2027(7)	04/14/2034	Class A Common Stock	150,888	$0.01	D
Stock Option (Right to Buy)	(10)	04/14/2034	Class A Common Stock	150,888	$0.01	D

Explanation of Responses:

1. Represents RSUs with each RSU representing the right to receive one share of Class A common stock. The RSUs vest in equal quarterly installments beginning February 15, 2025 through November 15, 2028, subject to the Reporting Person continuing to be a service provider through the applicable vesting date.

2. Represents RSUs with each RSU representing the right to receive one share of Class A common stock. The RSUs vest in equal quarterly installments beginning May 15, 2025 through February 15, 2029, subject to the Reporting Person continuing to be a service provider through the applicable vesting date.

3. The option vests as to one forty-eighth (1/48th) of the original 70,037 shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.

4. The option vests as to one forty-eighth (1/48th) of the original 740,686 shares subject to the option on January 2, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.

5. The option was vested as to 35,333 shares upon the Issuer's assumption of the option at the time of the acquisition of Exscientia plc on November 20, 2024, and the remaining 21,198 shares vest in equal amounts quarterly, starting on December 15, 2024 through March 15, 2026, subject to Reporting Person continuing as a service provider though each vesting date.

6. This option is vested and fully exercisable.

7. This option will become vested and exercisable on the Date Exercisable subject to the Reporting Person continuing as a service provider through such date.

8. The option was vested as to 30190 shares upon the Issuer's assumption of the option at the time of the acquisition of Exscientia plc on November 20, 2024, and the remaining 50,320 shares vest in equal amounts quarterly, starting on December 15, 2024 through March 15, 2027, subject to Reporting Person continuing as a service provider though each vesting date.

9. This option is vested and fully exercisable

10. The option was vested as to 18,862 shares upon the Issuer's assumption of the option at the time of the acquisition of Exscientia plc on November 20, 2024, and the remaining 132,026 shares vest in equal amounts quarterly, starting on December 15, 2024 through March 15, 2028, subject to Reporting Person continuing as a service provider though each vesting date.

Remarks:

	/s/Jonathan Golightly, attorney-in-fact	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the reporting person in the Recursion (RXRX) Form 3 filing?

The Form 3 identifies David Hallett as the reporting person. He is an officer of Recursion Pharmaceuticals, Inc. and serves as the company’s Chief Scientific Officer (CSO).

What Class A common stock holdings does David Hallett report in this RXRX Form 3?

David Hallett reports direct beneficial ownership of 287,928 shares of Class A common stock, along with RSU awards covering an additional 277,759 and 28,454 Class A shares, each RSU representing the right to receive one share upon vesting.

How do David Hallett’s RSUs in Recursion Pharmaceuticals vest?

One RSU grant of 277,759 shares vests in equal quarterly installments from February 15, 2025 through November 15, 2028. A second RSU grant of 28,454 shares vests in equal quarterly installments from May 15, 2025 through February 15, 2029, in each case subject to Hallett continuing as a service provider through the applicable vesting dates.

What stock options does David Hallett hold according to the RXRX Form 3?

Hallett holds several stock options (rights to buy Class A common stock), including options for 70,037 shares at an exercise price of $7.25 and 740,686 shares at $6.09, both vesting monthly after initial vesting dates in 2025. He also holds options at an exercise price of $0.01 for 56,531, 75,375, 80,510, 9,241, and 150,888 shares.

Are any of David Hallett’s Recursion stock options already fully vested?

Yes. One option described in the filing is stated as “vested and fully exercisable”, and another option tied to footnote F9 is also described as “vested and fully exercisable”. Other option grants vest over time according to monthly or quarterly schedules.

How are some of David Hallett’s options related to the Exscientia plc acquisition?

Certain options, including tranches noted in footnotes F5, F8, and F10, were partially vested when Recursion assumed them in connection with the acquisition of Exscientia plc on November 20, 2024. The remaining shares under these options vest in equal quarterly installments from December 15, 2024 through dates ranging from March 15, 2026 to March 15, 2028, subject to continued service.

Do any of David Hallett’s Recursion options vest on specific future dates?

Yes. The filing notes options that will become vested and exercisable on specific “Date Exercisable” milestones, including April 4, 2026 and April 17, 2027, provided Hallett continues as a service provider through those dates.